drugset / Trial / NCT06161974
Study of Olutasidenib and Temozolomide in HGG
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2029-06
- Completion
- 2035-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olutasidenib | Small molecule | 150 mg | Oral |
| Background | Temozolomide | Small molecule | 200 mg/m2 | Oral |